High-dose polychemotherapy of patients with poor-prognosis anaplastic T.0-large cell ALK+ lymphosarcoma


Cite item

Full Text

Abstract

Aim. To evaluate efficacy of the protocol NHL BFM-90 in the treatment of adult anaplastic large cell lymphosarcoma (ALCL) ALK+ and validity of addition of transplantation of autologous stem hemopoietic cells (ASHC) into first line treatment.
Material and methods. We treated 13 patients with stage III-IV ALCL ALK+. The age of the patients ranged from 17 to 44 years (median 26 years). The diagnosis was made using morphological, histological, immunohistochemical methods with application of monoclonal antibodies to CD30, ALK, CD3, CD4, CD8, CD7, CD34, CD15, CD68, CD20, CD45RO, CD45RA. The patients were treated according to the protocol NHL BFM-90. ASHC was made in two patients with the disease stage IV.
Results. We obtained a complete remission in 12 of 13 patients, one woman died of infectious complications in the beginning of the treatment, one man had early recurrence 45 days after the end of the treatment with lethal outcome and disease progression. Two patients at stage IV and poor prognosis had undergone ASHC transplantation. They are now in remission for 5 and 12 months.
Conclusion. ALCL ALK+ is characterized by an aggressive clinical course (11 of 13 patients had stage III-IV), high rate of extranodal lesions. Twelve patients achieved a complete remission, 11 (91.6%) of 12 patients are alive in observation median 27 months. We effectively used ASHC transplantation in the first-line treatment of 2 patients with stage IV of the disease and poor prognosis.

References

  1. Stein G., Foss H., Durcop H. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features. Blood 2000; 96(12): 3681-3695.
  2. Виноградова Ю. Е., Воробьев А. И. T-клеточные лимфатические опухоли. В кн.: Воробьев А. И. (ред.) Руководство по гематологии. 3-е изд. М.: Ньюдиамед; 2002: т. 2: 113-131.
  3. Kadin M. E., Sako D., Berliner N. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. Blood, 1986; 68: 1042.
  4. Benharoch D., Meguerian-Bedoyan Z., Lamant L. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood, 1999; 91(6): 2076-2084.
  5. Barberis A., Widenhorn K., Vitelli L. et al. A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation. Genes Dev. 1990; 4: 849.
  6. Jeffrey Medeiros L., Elenitoba-Johnson S. J. Anaplastic large cell lymphoma. Am. J. Clin. Pathol. 2007; 127: 707-722.
  7. Tilly H., Gaulard E., Lepage E. Primary anaplastic large cell lymphoma in adults: Immunophenotype, and outcome. Blood 1997; 90(9): 3727-3734.
  8. Семенова А. А., Сорокин Е. Н., Поддубная И. В. Анапластическая крупноклеточная лимфома взрослых: влияние прогностических факторов на терапию. Соврем. онкол. 2008; 2: 44-47.
  9. Fanin R., Sperotto A., Silvestri F. et al. The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center. Leukemia and Lymphoma 1999; 35(1-2): 159-169.
  10. Deconinck E., Lamy T., Foussard C. et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br. J. Haematol. 2000; 109(4): 736-742.
  11. Todeschini G., Tecchio C., Pasini F. Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897). Cancer 2005; 104(3): 555-560.
  12. Reiter A., Schrappe M., Tiemann M. Successful treatment strategy for Ki-1 anaplastic large cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J. Clin. Oncol. 1994; 12(5): 899-908.
  13. Reiter A. Diagnosis and treatment of childhood non-hodgkin lymphoma. In: Hematology. American Society of Hematology. Educational Program. 2007. 285-296. http://asheducationbook. Hematology library. org/cgi/content/abstr/2007/1/285.
  14. Виноградова Ю. Е., Луценко И. Н., Капланская И. Б. и др. Эффективность терапии различных вариантов T-клеточных анаплазированных крупноклеточных лимфом. Тер. арх. 2008; 80(7): 33-37.
  15. Gascoyne R., Aoun P., Wu D. et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913-3921.

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies